- US-listed companies
- Theravance Biopharma, Inc.
- Income statement
Theravance Biopharma, Inc. (TBPH) Income statement
Market cap
$849.63M
P/E ratio
8x
| 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Revenue | 12 | 42 | 49 | 15 | 60 | 73 | 72 | 55 | 51 | 57 | 64 | 107 |
| Revenue growth (%) | - | |||||||||||
| Cost of revenue | 4 | 5 | 3 | 6 | - | - | - | - | - | - | - | - |
| Research & development | 169 | 129 | 142 | 174 | 201 | 219 | 261 | 194 | 63 | 41 | 38 | 37 |
| Selling, general & administrative | 72 | 90 | 85 | 96 | 97 | 106 | 109 | 99 | 67 | 70 | 69 | 74 |
| Operating margin (%) | ||||||||||||
| Operating expenses | 244 | 224 | 229 | 276 | 299 | 325 | 370 | 313 | 143 | 113 | 111 | 111 |
| Operating income | -233 | -182 | -180 | -260 | -239 | -252 | -298 | -258 | -92 | -56 | -47 | -4 |
| Income before tax | -231 | -181 | -181 | -272 | -226 | -242 | -287 | -200 | -93 | -49 | -45 | 129 |
| Pretax margin (%) | -1,973.6 | -430.3 | -371.2 | -1,766 | -374.5 | -329.2 | -398.8 | -360.8 | -180.8 | -85.8 | -69.3 | 120.3 |
| Provision for income taxes | 6 | 1 | 10 | 14 | -11 | -5 | -8 | -0 | 0 | 6 | 12 | 23 |
| Effective tax rate (%) | ||||||||||||
| Net income | -237 | -182 | -191 | -285 | -216 | -236 | -278 | -199 | 872 | -55 | -56 | 106 |
| Net income margin (%) | ||||||||||||
| Earnings per share | - | - | - | - | - | - | - | -2.87 | 11.85 | -1 | -1.15 | 2.1 |
| Diluted EPS | - | - | - | - | - | - | - | -2.87 | 11.85 | -1 | -1.15 | 2.06 |
| EBITDA | - | - | - | - | - | - | - | |||||
| EBITDA margin (%) | - | - | - | - | - | - | - |